Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Titel:
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Auteur:
Vlaar, Alexander P J de Bruin, Sanne Busch, Matthias Timmermans, Sjoerd A M E G van Zeggeren, Ingeborg E Koning, Rutger ter Horst, Liora Bulle, Esther B van Baarle, Frank E H P van de Poll, Marcel C G Kemper, E Marleen van der Horst, Iwan C C Schultz, Marcus J Horn, Janneke Paulus, Frederique Bos, Lieuwe D Wiersinga, W Joost Witzenrath, Martin Rueckinger, Simon Pilz, Korinna Brouwer, Matthijs C Guo, Ren-Feng Heunks, Leo van Paassen, Pieter Riedemann, Niels C van de Beek, Diederik